Stock research

Align Technology, Inc. (ALGN) Stock Research

Align Technology makes Invisalign clear dental aligners and digital scanning systems for orthodontics.

For the fiscal year ended December 31, 2025, Align Technology, Inc. reported revenue of $4.0B and net income of $410M, with operating cash flow of $593M. Source: Form 10-K filed February 27, 2026

SEC data as of

Revenue
$4.0B
FY ending 2025-12-31
Net income
$410M
FY ending 2025-12-31
Diluted EPS
$5.65
Net margin
10.2%

Reported SEC XBRL figures. Each metric’s period and original filing are listed below.

Loading delayed market data…

Delayed Cboe One market data via TradingView. It may differ from primary-exchange or consolidated quotes.

About Align Technology

Exchange
NASDAQ: ALGN
Sector
Health Care
SEC industry
Orthopedic, Prosthetic & Surgical Appliances & Supplies (SIC 3842)
Fiscal year end
December 31

ALGN key financials

Reported figures from Align Technology, Inc.'s filings, pulled directly from SEC XBRL data rather than a third-party terminal. Each row links to the filing it came from.

MetricValuePeriodSource
Revenue$4.0B2025-01-01 – 2025-12-31SEC filing
Net income$410M2025-01-01 – 2025-12-31SEC filing
Operating cash flow$593M2025-01-01 – 2025-12-31SEC filing
Diluted EPS$5.652025-01-01 – 2025-12-31SEC filing
Net margin10.2%2025-01-01 – 2025-12-31SEC filing
Shares outstanding72MAs of 2025-10-29SEC filing

Values are as tagged by the issuer in XBRL. Revenue for banks and insurers is net of interest expense where that is the reported line. Fiscal years that do not follow the calendar are shown by their period-end date. No price, market cap, or valuation multiple is shown because Yield Theory does not republish unlicensed market data.

Diluted EPS is the earnings figure behind the price-to-earnings ratio; the P/E multiple compression calculator shows how a change in that multiple moves a share price. Shares outstanding multiplied by the share price gives market capitalization.

What investors should watch in ALGN

Align Technology, Inc. sits in Health Care. Pharmaceuticals, biotech, medical devices, and managed care — defensive demand paired with binary drug and regulatory catalysts. We have not yet written company-specific drivers for ALGN; the forces that matter most for the sector are:

  • ◆Drug approvals and clinical-trial readouts
  • ◆Medicare and drug-pricing policy
  • ◆Demographics and an aging population
  • ◆GLP-1 and obesity-drug demand

Key questions for the ALGN thesis

Each question starts with what the filings show, then why it matters. None of these is a rating or a forecast.

Does ALGN's reported profit turn into cash?

Operating cash flow was $593M, 1.45 times net income of $410M, for the fiscal year ended December 31, 2025.

Cash from operations exceeded reported earnings. Non-cash charges such as depreciation, amortization and stock-based compensation usually explain the gap; the cash-flow statement shows which.

Form 10-K filed February 27, 2026

How much of ALGN's revenue is left as profit?

Net income was 10.2% of revenue for the fiscal year ended December 31, 2025, based on revenue and net income reported for the same period.

Net margin reflects the business model as much as execution, so compare it with companies in the same SEC industry and read the income statement for one-time items before treating it as a run rate.

Form 10-K filed February 27, 2026

Members-only research

What members are reading this month

The thesis, the numbers behind it, and what would break it. Full access is $39 a month.

Read the full research

Congressional trading in ALGN

PoliticianTrade dateTypeOwnerAmountSource
Lisa McClain2025-09-11SaleSpouse$1,001 - $15,000Filing #20032129
Lisa McClain2025-08-04PurchaseSpouse$1,001 - $15,000Filing #20030932
Robert Bresnahan2025-04-08SaleSelf$1,001 - $15,000Filing #20030291
Gilbert Cisneros2025-02-26SaleSelf$1,001 - $15,000Filing #20027891
Robert Bresnahan2025-02-25PurchaseSelf$1,001 - $15,000Filing #20029034

All verified ALGN congressional disclosures

Congressional disclosures are delayed, range-based records—not real-time signals or proof of motive. See the source-linked tracker for scope and limitations.

ALGN — frequently asked questions

What does Align Technology, Inc. do?

Align Technology makes Invisalign clear dental aligners and digital scanning systems for orthodontics.

What were ALGN's latest reported annual revenue and net income?

For the fiscal year ended December 31, 2025, Align Technology, Inc. reported revenue of $4.0B and net income of $410M, with operating cash flow of $593M. The figures come from Align Technology, Inc.'s SEC XBRL filings.

When does Align Technology, Inc.'s fiscal year end?

The SEC lists Align Technology, Inc.'s fiscal year end as December 31.

Do members of Congress trade ALGN?

The current verified House and Senate snapshot contains 5 transaction rows for ALGN, each linked to the original filing.

Is ALGN a good investment?

This page does not rate ALGN as a buy or sell. It sets out what Align Technology, Inc. reports, what investors should watch and the questions a thesis has to answer, with links to the SEC filings. It is research, not investment advice.

This page is independent research and educational information, not investment advice or a recommendation to buy or sell any security. Company facts are compiled from public sources. Do your own research.

What do the ALGN numbers leave unanswered?

Financials describe the business. The next question is which assumptions an investment thesis depends on. Explore the member reports below for analysis of catalysts, risks, and what would change the view. $39/month or $249/year.

$39/mo or $249/yr · cancel future renewals anytime · sources included